AusperBio Therapeutics Raises $120 Million in Series C Funding
AusperBio Therapeutics, based in San Francisco, California, has secured $120 million in a Series C funding round. The company specializes in developing therapeutics for hepatitis B, with a focus on advancing its lead therapy, AHB-137, through clinical stages.
Investors and Leadership
The Series C round was led by a Strategic lead investor, with participation from RA Capital, HanKang Capital, Sherpa Capital, InnoPinnacle Fund, Qiming Venture Partners, YuanBio Venture Capital, and CDH Investments. Guofeng Cheng, Co-Founder and CEO of AusperBio, plays a pivotal role in steering the company's strategic direction.
Funding Utilization
The newly acquired capital will be directed towards preparing AHB-137 for a Phase 3 registrational program and potential commercialization. This funding emphasizes the company's commitment to clinical execution and regulatory milestones.
Conclusion
With this significant investment, AusperBio is well-positioned to advance its therapeutic solutions for hepatitis B, potentially impacting the healthcare landscape significantly.